Efficacy and Safety of Pembrolizumab or Pembrolizumab Plus Chemotherapy vs Chemotherapy Alone for Patients With First-line, Advanced Gastric Cancer

Kohei Shitara; Eric Van Cutsem; Yung‐Jue Bang; Charles S. Fuchs; Lucjan Wyrwicz; Keun‐Wook Lee; Iveta Kudaba; Marcelo Garrido; Hyun Cheol Chung; Jeeyun Lee; Hugo R. Castro; Wasat Mansoor; Maria Ignez Braghiroli; Nina Karaseva; Christian Caglevic; Luis J. Villanueva-Rivera; Eray Goekkurt; Hironaga Satake; Peter C. Enzinger; María Alsina; Al B. Benson; Joseph Chao; Andrew H. Ko; Zev A. Wainberg; Uma Kher; Sukrut Shah; Soonmo Peter Kang; Josep Tabernero

doi:10.1001/jamaoncol.2020.3370

Abstract

ClinicalTrials.gov Identifier: NCT02494583.

Keywords

PembrolizumabMedicineInternal medicineCapecitabineChemotherapyCancerOncologyGastroenterologySurgeryImmunotherapyColorectal cancer

Affiliated Institutions

Related Publications

Avelumab Maintenance Therapy for Advanced or Metastatic Urothelial Carcinoma

Thomas Powles , Se Hoon Park , Éric Voog +24 more

Maintenance avelumab plus best supportive care significantly prolonged overall survival, as compared with best supportive care alone, among patients with urothelial cancer who h...

2020 New England Journal of Medicine 1374 citations

Pembrolizumab alone or with chemotherapy versus cetuximab with chemotherapy for recurrent or metastatic squamous cell carcinoma of the head and neck (KEYNOTE-048): a randomised, open-label, phase 3 study

Barbara Burtness , Kevin J. Harrington , Richard Greil +97 more

Pembrolizumab is active in head and neck squamous cell carcinoma (HNSCC), with programmed cell death ligand 1 (PD-L1) expression associated with improved response. KEYNOTE-048 w...

2019 The Lancet 2928 citations

Perioperative chemotherapy with fluorouracil plus leucovorin, oxaliplatin, and docetaxel versus fluorouracil or capecitabine plus cisplatin and epirubicin for locally advanced, resectable gastric or gastro-oesophageal junction adenocarcinoma (FLOT4): a randomised, phase 2/3 trial

Salah‐Eddin Al‐Batran , Nils Homann , Claudia Pauligk +54 more

Docetaxel-based chemotherapy is effective in metastatic gastric and gastro-oesophageal junction adenocarcinoma. This study reports on the safety and efficacy of the docetaxel-ba...

2019 The Lancet 2355 citations

Atezolizumab in combination with carboplatin plus nab-paclitaxel chemotherapy compared with chemotherapy alone as first-line treatment for metastatic non-squamous non-small-cell lung cancer (IMpower130): a multicentre, randomised, open-label, phase 3 trial

Howard West , Michael McCleod , Maen Hussein +17 more

Atezolizumab (a monoclonal antibody against PD-L1), which restores anticancer immunity, improved overall survival in patients with previously treated non-small-cell lung cancer ...

2019 The Lancet Oncology 1597 citations

Pembrolizumab plus Chemotherapy for Squamous Non–Small-Cell Lung Cancer

Luis Paz‐Ares , Alexander Luft , David Vicente +20 more

In patients with previously untreated metastatic, squamous NSCLC, the addition of pembrolizumab to chemotherapy with carboplatin plus paclitaxel or nab-paclitaxel resulted in si...

2018 New England Journal of Medicine 3472 citations

Publication Info

Year: 2020
Type: article
Volume: 6
Issue: 10
Pages: 1571-1571
Citations: 1036
Access: Closed

External Links

View on DOI.org

Social Impact

Altmetric

Efficacy and Safety of Pembrolizumab or Pembrolizumab Plus Chemotherapy vs Chemotherapy Alone for Patients With First-line, Advanced Gastric Cancer

PlumX Metrics

Social media, news, blog, policy document mentions

Citation Metrics

1036

OpenAlex

Cite This

APA Style

                            
                                
                                    Kohei Shitara, 
                                
                                    Eric Van Cutsem, 
                                
                                    Yung‐Jue Bang
                                
                                et al.
                            
                            (2020). 
                            Efficacy and Safety of Pembrolizumab or Pembrolizumab Plus Chemotherapy vs Chemotherapy Alone for Patients With First-line, Advanced Gastric Cancer. 
                            JAMA Oncology
                            , 6
                            (10)
                            , 1571-1571.
                            https://doi.org/10.1001/jamaoncol.2020.3370
                        

Identifiers

DOI: 10.1001/jamaoncol.2020.3370